Beyond Borders: The Global Biotechnology ReportErnst & Young, 2006 - Biotechnology |
Contents
Global Introduction | 1 |
Global Industry Perspective | 7 |
Canada Year in Review | 60 |
1 other sections not shown
Other editions - View all
Common terms and phrases
acquisition Amgen antibodies aptamers Asia-Pacific Asian avian flu big pharma BioCentury biofuels Biogen Idec biologics biotech companies biotech industry biotech sector biotechnology biotechnology companies biotechnology industry BioWorld boost Canada Canadian cancer challenges China Chinese clinical trials commercialization compa competitive costs deals diagnostic diseases drug development drug discovery early-stage emerging equity Ernst & Young Europe European biotech financing firms focus focused funding gene Genentech genetic Genomics Germany GlaxoSmithKline Global Biotechnology growth increased India industry's initial public offerings innovative investment investors late-stage launched M&As manufacturing market capitalization medicine ment mergers million molecular nology Novartis panies partners patent percent performance Pharmaceuticals Phase pipeline potential product approvals programs proteins public companies Qiagen recent recombinant regulatory revenues rounds segment SFDA significant Source startup stem cell strategic alliances strong success Switzerland targeted tech therapeutics therapies tion trends ucts vaccines VentureOne